6月4日，西维斯健康盘中上涨3.29%，报94.245美元/股，成交额3.19亿美元。消息面上，多重利好共振推动股价走强。
投行方面，大摩将CVS Health目标价从106美元上调至111美元，维持跑赢大盘评级；此前Truist亦将目标价从102美元上调至108美元，维持买入评级。业务层面，公司旗下药房福利管理部门CVS Caremark宣布更新商业处方集，将自10月1日起恢复对礼来减肥注射剂Zepbound的覆盖，并纳入新型口服减肥药Foundayo。公司表示此举系与药企谈判降低成本的成果，旨在为投保人提供更广泛的GLP-1类药物选择，市场预期此举将增强其药房福利管理业务的竞争力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.